Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303400 | 1.00 | ATM (0.39) | ATMRIPK1PIK3CDPDK1DPP4 | |
| SCHEMBL23136538 | 0.87 | ATM (0.46) | ATMRIPK1PIK3CDPDK1DPP4 | |
| SCHEMBL29243192 | 0.85 | ATM (0.34) | ATMRIPK1PIK3CDPDK1DPP4 | |
| SCHEMBL29243194 | 0.85 | ATM (0.34) | ATMRIPK1PIK3CDPDK1DPP4 | |
| SCHEMBL4296899 | 0.85 | MMP2 (0.37) | PDK1 | |
| SCHEMBL376752 | 0.85 | MMP2 (0.37) | PDK1 | |
| SCHEMBL3469309 | 0.83 | ATM (0.41) | ATMRIPK1PIK3CDPDK1DPP4 | |
| SCHEMBL376240 | 0.83 | ATM (0.41) | ATMRIPK1PIK3CDPDK1DPP4 | |
| SCHEMBL3950963 | 0.83 | ATM (0.41) | ATMRIPK1PIK3CDPDK1DPP4 | |
| SCHEMBL29243217 | 0.83 | ATM (0.41) | ATMRIPK1PIK3CDPDK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | ATM 1181/4885RIPK1 517/4885PIK3CD 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.